Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer

Journal of Clinical Oncology

Volumn 34, Issue 36, 2016, Pages 4345-4353

  Isabelle, Ray Coquard ^f   Isabelle, Tabah Fisch ^b   Eric, Pujade Lauraine ^h   Liu, Joyce F ^a   Selle, Frederic ^g   Poveda, Andŕes M ^j   Cibula, David ^l   Hirte, Hal ^m   Hilpert, Felix ⁿ   Raspagliesi, Francesco ^p   Gladieff, Laurence ⁱ   Harter, Philipp ^o   Siena, Salvatore ^q   Del Campo, Josep Maria ^k   Pearlberg, Joseph ^b   Moyo, Victor ^c   Riahi, Kaveh ^c   Nering, Rachel ^c   Kubasek, William ^e   Adiwijaya, Bambang ^c   Czibere, Akos ^c   Naumann, R Wendel ^d   Coleman, Robert L ^f   Vergote, Ignace ^r   MacBeath, Gavin ^c   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Sanofi Oncology   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITÉ LYON 1   (France)

^g HÔPITAL TENON   (France)

^h HÔTEL DIEU   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

^j INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l CHARLES UNIVERSITY   (Czech Republic)

^m HAMILTON HEALTH SCIENCES   (Canada)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o KLINIKEN ESSEN MITTE   (Germany)

^p Istituto Nazionale dei Tumori   (Italy)

^q UNIVERSITY OF MILAN   (Italy)

^r UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PACLITAXEL; SERIBANTUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEEDLE BIOPSY; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VOMITING; AGED; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85009816442     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.1891     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods andmajor patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015.
2. Naumann RW, Coleman RL: Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397-1412, 2011.
3. Lortholary A, Largillier R, Weber B, et al: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23:346-352, 2012.
4. Poveda AM, Selle F, Hilpert F, et al: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836-3838, 2015.
5. Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30:362-371, 2012.
6. Monk BJ, Poveda A, Vergote I, et al: Antiangiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799-808, 2014.
7. Holohan C, Van Schaeybroeck S, Longley DB, et al: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13:714-726, 2013.
8. Leto SM, Trusolino L: Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: Impact on future treatment strategies. J Mol Med (Berl) 92:709-722, 2014.
9. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-509, 2012.
10. Amin DN, Campbell MR, Moasser MM: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21:944-950, 2010.
11. Bezler M, Hengstler JG, Ullrich A: Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 6:516-529, 2012.
12. Chakrabarty A, Śanchez V, Kuba MG, et al: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718-2723, 2012.
13. Hellyer NJ, Kim MS, Koland JG: Heregulindependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 276:42153-42161, 2001.
14. Ma J, Lyu H, Huang J, et al: Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer 13:105, 2014.
15. Schoeberl B, Faber AC, Li D, et al: An ErbB3 antibody, MM-121, is active in cancers with liganddependent activation. Cancer Res 70:2485-2494, 2010.
16. Sheng Q, Liu X, Fleming E, et al: An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17: 298-310, 2010.
17. Schoeberl B, Pace EA, Fitzgerald JB, et al: Therapeutically targeting ErbB3: A key node in ligandinduced activation of the ErbB receptor-PI3K axis. Sci Signal 2:ra31, 2009.
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009.
20. Markman M, Bookman MA: Second-line treatment of ovarian cancer. Oncologist 5:26-35, 2000.
21. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12: 1748-1753, 1994.
22. Onsum MD, Geretti E, Paragas V, et al: Singlecell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol 183: 1446-1460, 2013.
23. Frogne T, Benjaminsen R V, Sonne-Hansen K, et al: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114:263-275, 2009.
24. Wang S, Huang J, Lyu H, et al: Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 15: R101, 2013.
25. Onsum M, Yarar D, Paragas V, et al: Abstract 4945: Targeting ErbB3-addicted cancers across the HER2 spectrum. Cancer Res 72, 2012 (abstr 4945).
26. Langer CJ, Novello S, Park K, et al: Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 32: 2059-2066, 2014.
27. Sclafani F, Kim TY, Cunningham D, et al: A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J Natl Cancer Inst 107:258, 2015.
28. Bokemeyer C, Van Cutsem E, Rougier P, et al: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466-1475, 2012.
29. Douillard J-Y, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013.
30. Spigel DR, Ervin TJ, Ramlau RA, et al: Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-smallcell lung cancer. J Clin Oncol 31:4105-4114, 2013.
31. Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinumresistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215-1223, 2010.
32. Higgins MJ, Doyle C, Paepke S, et al: A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 587).
33. MacBeath G, Adiwijaya B, Liu J, et al: A metaanalysis of biomarkers in three randomized, phase 2 stuides of MM-121, a ligand blocking anti-ErbB3 antibody, in patients with ovarian, lung and breast cancers. Presented at the 39th Congress of the European Society for Medical Oncology, Madrid, Spain, September 26-30, 2014.
34. Sequist LV, Lopez-Chavez A, Doebele RC, et al: A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 8051).
35. Mendell J, Freeman DJ, FengW, et al: Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer. E Bio Medicine 2:264-271, 2015.
36. Qian G, Jiang N, Wang D, et al: Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer 121:3600-3611, 2015.